iCell Gene Therapeutics
PrivateLast Round
Grant
Oct 8, 2020
Total Funding Raised
$3.1M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
iCell Gene Therapeutics operates in Healthcare & Life Sciences and is based in Stony Brook, New York. Its latest recorded funding round was a Grant round in October 2020.
iCell Gene Therapeutics is a biotechnology company that develops chimeric antigen receptor (CAR) immunotherapies for the treatment of autoimmune diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iCell Gene Therapeutics Comparables
Compare iCell Gene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Luminary Therapeutics, Inc. | 82% | |
| AstraZeneca | 81% | |
| Lyell Immunopharma | 77% |
For institutional investors. Book with your work email.
iCell Gene Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
iCell Gene Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Long Island High Technology Incubator | Accelerator |
| Food and Drug Administration | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
Open roles increased from 0 to 7, representing 47% of headcount.
- Aug 29, 2026
Grew 25% QoQ, from 12 to 15 employees.
For institutional investors. Book with your work email.
iCell Gene Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about iCell Gene Therapeutics's valuation, stock price, and market status.
Is iCell Gene Therapeutics a public or private company?
iCell Gene Therapeutics is a private company.
What is the current stock price of iCell Gene Therapeutics?
iCell Gene Therapeutics is a private company, so its shares have no public market price. Caplight tracks iCell Gene Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iCell Gene Therapeutics worth (valuation)?
Valuation information for iCell Gene Therapeutics is not publicly available.
Can I buy iCell Gene Therapeutics stock?
iCell Gene Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iCell Gene Therapeutics's last funding round?
iCell Gene Therapeutics's most recent funding round was Grant on October 8, 2020.
Who are the main investors in iCell Gene Therapeutics?
Key investors in iCell Gene Therapeutics include Long Island High Technology Incubator, Food and Drug Administration.
Will iCell Gene Therapeutics IPO soon?
No public IPO plans have been announced for iCell Gene Therapeutics.
How can I track iCell Gene Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in iCell Gene Therapeutics's shares on secondary markets.